Related Experiment Video
Updated: Mar 21, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.8K
Bosutinib for Chronic Myeloid Leukemia
Massimo Breccia1, Gianni Binotto2
1Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161 Rome, Italy.
Rare Cancers and Therapy
|May 17, 2016
Summary
Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment. Bosutinib offers an effective option for patients intolerant or resistant to imatinib, with a manageable safety profile.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) treatment has evolved with tyrosine kinase inhibitors (TKIs).
- Imatinib, a first-generation TKI, is effective but discontinued by 30-40% of patients due to failure or intolerance.
- Second-generation TKIs offer improved potency and response rates for imatinib-unsuitable patients.
Approach:
- This review summarizes preclinical and clinical data for bosutinib, a Src/Abl TKI.
- Bosutinib demonstrates in vitro efficacy against CML cells resistant to other TKIs (excluding T315I/V299L mutations).
- Clinical development highlights bosutinib's manageable safety profile in various treatment settings.
Key Points:
- Bosutinib is effective against imatinib-resistant CML cell lines lacking specific mutations.
- The drug exhibits a manageable safety profile during clinical trials.
- Bosutinib represents a valuable therapeutic option for specific CML patient populations.
Conclusions:
- Bosutinib is a potent TKI with efficacy in preclinical models of resistant CML.
- Clinical data support bosutinib's use with a manageable safety profile.
- This review discusses bosutinib's role alongside other TKIs in CML management.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:57Targeted Cancer Therapies
1.7K
1.7K
02:56Treatment Resistent Cancers
1.5K
1.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631